Developer docs
API playgroundTry for free, no card

Search company profiles

Celadon Pharmaceuticals

Full company profile

uuid00062h8

Namestring
Celadon Pharmaceuticals
Legal namestring
Celadon Pharmaceuticals Plc
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Celadon Pharmaceuticals is a UK-based, vertically integrated pharmaceutical company founded in 2018 that manufactures and supplies EU-GMP certified cannabis-based active pharmaceutical ingredients (APIs) for prescription medicines. The company operates a 100,000 sq ft facility in the West Midlands combining indoor hydroponic cultivation, proprietary GMP extraction, and an analytical R&D laboratory, all operating under an MHRA EU-GMP registration, a Home Office Controlled Drug Licence covering Schedules 1 and 2, and a General Pharmaceutical Council registration. Its core products are pharmaceutical-grade cannabis flower and oil APIs (strains RX11, Zerberry, OZARK and bespoke oil formulations) targeting chronic pain (an estimated 8 million UK adults) and endometriosis (approximately 1.5 million UK women). Business model is enterprise B2B: multi-year minimum-volume supply contracts with pharmaceutical and healthcare counterparties, IP and genetics licensing to European partners (Valeos Pharma A/S generates £1.5m annual licensing), and clinical-evidence generation via the majority-owned LVL Health subsidiary running the MHRA-approved CANPAIN chronic-pain trial designed to support NHS reimbursement. Pipeline products include Celendra (Delta-9 THC vaginal pessary for endometriosis, target launch 2026) and CLD-927 (semi-synthetic Delta-9 THC, target 2026), with a partnered autism spectrum disorder programme (KT-20610) via minority stake in Kingdom Therapeutics.

Short descriptiontext

Celadon Pharmaceuticals is a UK-based, vertically integrated pharmaceutical company that manufactures EU-GMP certified cannabis APIs and runs the MHRA-approved CANPAIN chronic-pain trial via its LVL Health subsidiary to support NHS reimbursement.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid active pharmaceutical ingredients, pharmaceutical-grade cannabis cultivation, GMP-compliant API manufacturing, cannabis-based medicines, clinical drug development
Industry1 code
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Cannabinoid Active Pharmaceutical Ingredients
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1GMP Cannabis API Sales
TypeTransaction Fee
Description

Sale of pharmaceutical-grade high-THC cannabis API to pharmaceutical companies for development of medicines and finished products. First contract: minimum £3m over 3 years. Second UK contract: £3m over 3 years. European contract: up to £26m over 3 years. New healthcare contract: up to £10.5m over 5 years.

celadonpharma.com
2Specials Framework Sales
TypeTransaction Fee
Description

Sale of cannabis-based medicines under UK 'Specials' framework, allowing prescription medicines without standard marketing authorisation for specific patient needs.

celadonpharma.com
3IP Licensing Revenue
TypeLicensing Royalties
Description

Licensing of genetics and intellectual property to European partners. Collaboration with Valeos Pharma A/S generating £1.5m annual licensing fee plus doubled cultivation capacity.

celadonpharma.com
4Clinical Trial Data Services
TypeProfessional Services
Description

Generating clinical trial data through LVL Health for NHS reimbursement, creating value through evidence-based medicine data that supports prescribing and insurance reimbursement.

celadonpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Pricing details3 tiers
1UK Supply Contract - Minimum £3m over 3 years
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

Contract with leading UK medicinal cannabis company for minimum £3m worth of product over 3 years, extendable for 2 more years.

celadonpharma.com
2European Sales Contract - Up to £26m over 3 years
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

Contract with leading European medicinal cannabis company, potential £26m revenue over 3-year term.

celadonpharma.com
3Healthcare Contract - Up to £10.5m over 5 years
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

Five-year contract with healthcare company with minimum order quantities, volumes increasing from year one to year three.

celadonpharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Celadon cultivates cannabis indoors and extracts and manufactures EU-GMP cannabinoid active pharmaceutical ingredients for pharmaceutical companies. Its commercial offer includes pharmaceutical-grade cannabis flower and oil APIs, high-THC API supplied through the UK Specials framework, cannabis genetics and intellectual-property licensing, and chronic-pain clinical services through LVL Health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 49.6% reduction in pain scores in first month of cannabis-based medicine treatment, sustained throughout 3-month study
+4 more records
Product overview1 text field

Celadon Pharmaceuticals operates as a vertically integrated pharmaceutical company with a unified platform approach encompassing cultivation, extraction, manufacturing, and clinical development of cannabis-based medicines. The core product is the GMP Cannabis API portfolio, including multiple cannabis flower strains (CEL-F15/0/RX11, CEL-F20/0/Zerberry, CEL-F19/0/OZARK) and Cannabis Oil API. The CANPAIN clinical trial, operated through subsidiary LVL Health, generates clinical evidence for NHS reimbursement. In development are pipeline products including Delta-9 THC vaginal pessary (Celendra) for endometriosis and Semi-Synthetic Delta-9 THC (CLD-927), alongside partnered programmes such as KT-20610 for autism spectrum disorder through Kingdom Therapeutics. The company also offers API for UK 'specials' prescription medicines.

Product and service10 records
1GMP Cannabis API
CategoryCannabinoid active pharmaceutical ingredients
Description

EU-GMP certified active pharmaceutical ingredients produced from cannabis plants for pharmaceutical customers, including flower and oil APIs spanning THC, CBD, CBG, CBC, CBN, and their acidic precursors.

2CEL-F15/0 (RX11)
CategoryPharmaceutical-grade cannabis flower API
Description

A cannabis strain derived from RX11 genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.

3CEL-F20/0 (Zerberry)
CategoryPharmaceutical-grade cannabis flower API
Description

A cannabis strain derived from Zerberry genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.

4CEL-F19/0 (OZARK)
CategoryPharmaceutical-grade cannabis flower API
Description

A cannabis strain derived from Ozark genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.

5Cannabis Oil API
CategoryCannabinoid oil active pharmaceutical ingredients
Description

Cannabis-oil APIs extracted from cannabis plants using Celadon's extraction facilities and processes, including proprietary formulations developed for eventual licensing as approved medicines.

6High-THC API for Specials
CategoryCannabis-based prescription medicines
Description

UK Specials prescription medicines using high-THC active pharmaceutical ingredient for patients underserved by available treatments, with a focus on chronic pain and endometriosis.

7Cannabis Genetics and Intellectual Property Licensing
CategoryPharmaceutical genetics and intellectual property licensing
Description

Licensing of Celadon's cannabis genetics and intellectual property to European partners, including a collaboration carrying a £1.5 million annual licensing fee.

8LVL Health Chronic Pain Clinic
CategorySpecialist chronic-pain healthcare services
Description

A private chronic-pain clinic providing cannabis-based medicines and operating the CANPAIN clinical trial through Celadon's majority-owned LVL Health subsidiary.

9Delta-9 THC Vaginal Pessary (Celendra)
CategoryCannabinoid prescription medicine
Description

A proprietary Delta-9 THC vaginal pessary under development for patients with endometriosis-associated pain, accompanied by an observational study.

10Semi-Synthetic Delta-9 THC (CLD-927)
CategorySemi-synthetic cannabinoid active pharmaceutical ingredient
Description

A semi-synthetic Delta-9 THC API that extends Celadon's pharmaceutical manufacturing capability beyond its plant-derived route.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Valeos Pharma A/S
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Strategic collaboration with Danish EU-GMP cultivator Valeos Pharma A/S announced September 2024. Allows Celadon to supply its European customer (worth up to £26m over 3 years) from Valeos' Danish facility, doubling cultivation capacity and generating £1.5m annual licensing fee plus up to £8m annual revenue.

celadonpharma.com
Strategic tierMinorTypeOthersAnnounced on2024-03-01
Description

Engaged YHEC to conduct comprehensive and independent review of feasibility study data and construct early economic model for NHS reimbursement discussions.

3U.S. DEA-Licensed Customer
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

First international shipment approved to a U.S. DEA-licensed customer, establishing compliant export into the U.S. market and marking significant international expansion.

celadonpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

Collaboration with Phytome announced September 2022 to explore potential of cannabis-based medicines in therapeutic areas with unmet need beyond the company's primary focus.

5LVL Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Celadon acquired majority shareholding in LVL Health, which operates the only MHRA conditionally approved clinical trial (CANPAIN) using cannabis-based medicinal products to treat chronic pain. LVL also runs a private pain clinic with CQC-approved physical clinic on Harley Street. The trial aims for NHS reimbursement and involves up to 5,000 patients.

celadonpharma.com
6Kingdom Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Celadon holds a minority equity stake in Kingdom Therapeutics, a UK biopharma developing a licensed cannabinoid medicine (KT-20610) to treat children with Autism Spectrum Disorder. The treatment targets gastrointestinal permeability linked to ASD. Celadon has option to supply API as development progresses.

celadonpharma.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The original UK-listed cannabinoid pharmaceutical company (Sativex, Epidiolex), now owned by Jazz Pharmaceuticals. Directly comparable as a GMP-certified cannabis-derived prescription medicine developer with similar regulatory pathway and NHS/private reimbursement strategy.

2Tilray Brands
TypeBroad incumbent
Description

Large global cannabis operator with pharmaceutical-grade cultivation and EU-GMP production across multiple geographies. Comparable as a vertically integrated cannabis API and finished product supplier, but with much broader consumer/cannabis portfolio beyond pharma.

TypeBroad incumbent
Description

Major global cannabis company with EU-GMP certified cultivation and pharmaceutical-grade cannabis products. Comparable in producing pharmaceutical cannabinoid APIs but operates at materially larger scale and across consumer/medical/industrial cannabis segments.

TypeBroad incumbent
Description

Canadian licensed producer with EU-GMP certified EU facilities producing medical cannabis flower and APIs for European pharmaceutical distribution. Overlaps with Celadon's European supply model and EU-GMP API strategy at larger scale.

TypeBroad incumbent
Description

Global cannabis company with EU-GMP certified production capabilities and pharmaceutical partnerships. Operates a broader consumer/medical cannabis portfolio while overlapping with Celadon in regulated medical cannabis API supply.

TypeDirect peer
Description

Canadian licensed producer with EU-GMP certified facilities and pharmaceutical cannabis export programs to Europe. Closely comparable as a mid-sized cannabis pharmaceutical API and finished product manufacturer pursuing international expansion.

TypeDirect peer
Description

Vertically integrated cannabis company with EU-GMP Colombian operations and a clinical focus on chronic pain, neurological conditions, and dermatology. Comparable in combining pharmaceutical-grade production with clinical evidence generation for medical cannabis prescribing.

8MGC Pharmaceuticals
TypeDirect peer
Description

UK/Australia-listed pharmaceutical cannabis company producing GMP cannabinoid medicines for chronic pain, epilepsy, and oncology indications. Closely comparable as a small-cap cannabis pharma with clinical development focus and similar regulatory pathway.

TypeDirect peer
Description

UK-listed cannabinoid pharmaceutical company developing prescription medicines for chronic pain and inflammatory conditions. Comparable as a UK small-cap focusing on clinical evidence for cannabinoid-based pharmaceuticals targeting similar indications.

10Valeos Pharma A/S
TypeRegional player
Description

Danish EU-GMP cultivator and Celadon's strategic collaboration partner since September 2024, enabling European supply from Danish facility. Comparable as an EU-based GMP cannabis cultivator and direct operational partner rather than a competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celadon Pharmaceuticals

Cannabinoid Active Pharmaceutical Ingredientsceladonpharma.com

Celadon Pharmaceuticals is a UK-based, vertically integrated pharmaceutical company that manufactures EU-GMP certified cannabis APIs and runs the MHRA-approved CANPAIN chronic-pain trial via its LVL Health subsidiary to support NHS reimbursement.

What Celadon Pharmaceuticals does

Celadon Pharmaceuticals is a UK-based, vertically integrated pharmaceutical company founded in 2018 that manufactures and supplies EU-GMP certified cannabis-based active pharmaceutical ingredients (APIs) for prescription medicines. The company operates a 100,000 sq ft facility in the West Midlands combining indoor hydroponic cultivation, proprietary GMP extraction, and an analytical R&D laboratory, all operating under an MHRA EU-GMP registration, a Home Office Controlled Drug Licence covering Schedules 1 and 2, and a General Pharmaceutical Council registration. Its core products are pharmaceutical-grade cannabis flower and oil APIs (strains RX11, Zerberry, OZARK and bespoke oil formulations) targeting chronic pain (an estimated 8 million UK adults) and endometriosis (approximately 1.5 million UK women). Business model is enterprise B2B: multi-year minimum-volume supply contracts with pharmaceutical and healthcare counterparties, IP and genetics licensing to European partners (Valeos Pharma A/S generates £1.5m annual licensing), and clinical-evidence generation via the majority-owned LVL Health subsidiary running the MHRA-approved CANPAIN chronic-pain trial designed to support NHS reimbursement. Pipeline products include Celendra (Delta-9 THC vaginal pessary for endometriosis, target launch 2026) and CLD-927 (semi-synthetic Delta-9 THC, target 2026), with a partnered autism spectrum disorder programme (KT-20610) via minority stake in Kingdom Therapeutics.

Celadon Pharmaceuticals firmographics

Firmographics
Name
Celadon Pharmaceuticals
Legal name
Celadon Pharmaceuticals Plc
Website
https://celadonpharma.com
Company type
Public
Founded year
2018
Headcount range
11–50 employees
Short description
Celadon Pharmaceuticals is a UK-based, vertically integrated pharmaceutical company that manufactures EU-GMP certified cannabis APIs and runs the MHRA-approved CANPAIN chronic-pain trial via its LVL Health subsidiary to support NHS reimbursement.
Ownership category
akta.pro rank

Celadon Pharmaceuticals industry classification

Industry
Product category
Cannabinoid Active Pharmaceutical Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Cannabinoid active pharmaceutical ingredients
  • Pharmaceutical-grade cannabis cultivation
  • GMP-compliant API manufacturing
  • Cannabis-based medicines
  • Clinical drug development

Where Celadon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Celadon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. GMP Cannabis API Sales: Sale of pharmaceutical-grade high-THC cannabis API to pharmaceutical companies for development of medicines and finished products. First contract: minimum £3m over 3 years. Second UK contract: £3m over 3 years. European contract: up to £26m over 3 years. New healthcare contract: up to £10.5m over 5 years.
  2. Specials Framework Sales: Sale of cannabis-based medicines under UK 'Specials' framework, allowing prescription medicines without standard marketing authorisation for specific patient needs.
  3. IP Licensing Revenue: Licensing of genetics and intellectual property to European partners. Collaboration with Valeos Pharma A/S generating £1.5m annual licensing fee plus doubled cultivation capacity.
  4. Clinical Trial Data Services: Generating clinical trial data through LVL Health for NHS reimbursement, creating value through evidence-based medicine data that supports prescribing and insurance reimbursement.

Pricing tiers

ModelBillingPrice
Transaction based/ take rateMulti-year contractUK Supply Contract - Minimum £3m over 3 years
Transaction based/ take rateMulti-year contractEuropean Sales Contract - Up to £26m over 3 years
Transaction based/ take rateMulti-year contractHealthcare Contract - Up to £10.5m over 5 years

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Celadon Pharmaceuticals product offering

Product offering

Core offering

Celadon cultivates cannabis indoors and extracts and manufactures EU-GMP cannabinoid active pharmaceutical ingredients for pharmaceutical companies. Its commercial offer includes pharmaceutical-grade cannabis flower and oil APIs, high-THC API supplied through the UK Specials framework, cannabis genetics and intellectual-property licensing, and chronic-pain clinical services through LVL Health.

Product overview

Celadon Pharmaceuticals operates as a vertically integrated pharmaceutical company with a unified platform approach encompassing cultivation, extraction, manufacturing, and clinical development of cannabis-based medicines. The core product is the GMP Cannabis API portfolio, including multiple cannabis flower strains (CEL-F15/0/RX11, CEL-F20/0/Zerberry, CEL-F19/0/OZARK) and Cannabis Oil API. The CANPAIN clinical trial, operated through subsidiary LVL Health, generates clinical evidence for NHS reimbursement. In development are pipeline products including Delta-9 THC vaginal pessary (Celendra) for endometriosis and Semi-Synthetic Delta-9 THC (CLD-927), alongside partnered programmes such as KT-20610 for autism spectrum disorder through Kingdom Therapeutics. The company also offers API for UK 'specials' prescription medicines.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMP Cannabis API EU-GMP certified active pharmaceutical ingredients produced from cannabis plants for pharmaceutical customers, including flower and oil APIs spanning THC, CBD, CBG, CBC, CBN, and their acidic precursors.
  • CEL-F15/0 (RX11) A cannabis strain derived from RX11 genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.
  • CEL-F20/0 (Zerberry) A cannabis strain derived from Zerberry genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.
  • CEL-F19/0 (OZARK) A cannabis strain derived from Ozark genetics and cultivated to GMP pharmaceutical-grade standards for consistent quality and stability.
  • Cannabis Oil API Cannabis-oil APIs extracted from cannabis plants using Celadon's extraction facilities and processes, including proprietary formulations developed for eventual licensing as approved medicines.
  • High-THC API for Specials UK Specials prescription medicines using high-THC active pharmaceutical ingredient for patients underserved by available treatments, with a focus on chronic pain and endometriosis.
  • Cannabis Genetics and Intellectual Property Licensing Licensing of Celadon's cannabis genetics and intellectual property to European partners, including a collaboration carrying a £1.5 million annual licensing fee.
  • LVL Health Chronic Pain Clinic A private chronic-pain clinic providing cannabis-based medicines and operating the CANPAIN clinical trial through Celadon's majority-owned LVL Health subsidiary.
  • Delta-9 THC Vaginal Pessary (Celendra) A proprietary Delta-9 THC vaginal pessary under development for patients with endometriosis-associated pain, accompanied by an observational study.
  • Semi-Synthetic Delta-9 THC (CLD-927) A semi-synthetic Delta-9 THC API that extends Celadon's pharmaceutical manufacturing capability beyond its plant-derived route.

Quantifiable outcome

  • 49.6% reduction in pain scores in first month of cannabis-based medicine treatment, sustained throughout 3-month study
  • +4 more outcomes

Companies that use Celadon Pharmaceuticals

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Celadon Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Celadon Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Valeos Pharma A/ScoreStrategic or Co-development Partner · 1 September 2024Strategic collaboration with Danish EU-GMP cultivator Valeos Pharma A/S announced September 2024. Allows Celadon to supply its European customer (worth up to £26m over 3 years) from Valeos' Danish facility, doubling cultivation capacity and generating £1.5m annual licensing fee plus up to £8m annual revenue.
  • York Health Economic Consulting (YHEC)minorOthers · 1 March 2024Engaged YHEC to conduct comprehensive and independent review of feasibility study data and construct early economic model for NHS reimbursement discussions.
  • U.S. DEA-Licensed CustomercoreChannel Partner/ Reseller/ Distributor · 1 January 2024First international shipment approved to a U.S. DEA-licensed customer, establishing compliant export into the U.S. market and marking significant international expansion.
  • PhytomeminorStrategic or Co-development Partner · 1 September 2022Collaboration with Phytome announced September 2022 to explore potential of cannabis-based medicines in therapeutic areas with unmet need beyond the company's primary focus.
  • LVL HealthcoreStrategic or Co-development Partner · 1 January 2021Celadon acquired majority shareholding in LVL Health, which operates the only MHRA conditionally approved clinical trial (CANPAIN) using cannabis-based medicinal products to treat chronic pain. LVL also runs a private pain clinic with CQC-approved physical clinic on Harley Street. The trial aims for NHS reimbursement and involves up to 5,000 patients.
  • Kingdom TherapeuticscoreStrategic or Co-development Partner · 1 January 2021Celadon holds a minority equity stake in Kingdom Therapeutics, a UK biopharma developing a licensed cannabinoid medicine (KT-20610) to treat children with Autism Spectrum Disorder. The treatment targets gastrointestinal permeability linked to ASD. Celadon has option to supply API as development progresses.

Scale indicators12 records

Recent moves9 records

Expansion highlights7 records

Celadon Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • GW Pharmaceuticals (Jazz Pharmaceuticals): The original UK-listed cannabinoid pharmaceutical company (Sativex, Epidiolex), now owned by Jazz Pharmaceuticals. Directly comparable as a GMP-certified cannabis-derived prescription medicine developer with similar regulatory pathway and NHS/private reimbursement strategy.
  • Organigram Holdings: Canadian licensed producer with EU-GMP certified facilities and pharmaceutical cannabis export programs to Europe. Closely comparable as a mid-sized cannabis pharmaceutical API and finished product manufacturer pursuing international expansion.
  • Khiron Life Sciences: Vertically integrated cannabis company with EU-GMP Colombian operations and a clinical focus on chronic pain, neurological conditions, and dermatology. Comparable in combining pharmaceutical-grade production with clinical evidence generation for medical cannabis prescribing.
  • MGC Pharmaceuticals: UK/Australia-listed pharmaceutical cannabis company producing GMP cannabinoid medicines for chronic pain, epilepsy, and oncology indications. Closely comparable as a small-cap cannabis pharma with clinical development focus and similar regulatory pathway.
  • Oxford Cannabinoid Technologies: UK-listed cannabinoid pharmaceutical company developing prescription medicines for chronic pain and inflammatory conditions. Comparable as a UK small-cap focusing on clinical evidence for cannabinoid-based pharmaceuticals targeting similar indications.

Broad incumbents

  • Tilray Brands: Large global cannabis operator with pharmaceutical-grade cultivation and EU-GMP production across multiple geographies. Comparable as a vertically integrated cannabis API and finished product supplier, but with much broader consumer/cannabis portfolio beyond pharma.
  • Canopy Growth: Major global cannabis company with EU-GMP certified cultivation and pharmaceutical-grade cannabis products. Comparable in producing pharmaceutical cannabinoid APIs but operates at materially larger scale and across consumer/medical/industrial cannabis segments.
  • Aurora Cannabis: Canadian licensed producer with EU-GMP certified EU facilities producing medical cannabis flower and APIs for European pharmaceutical distribution. Overlaps with Celadon's European supply model and EU-GMP API strategy at larger scale.
  • Cronos Group: Global cannabis company with EU-GMP certified production capabilities and pharmaceutical partnerships. Operates a broader consumer/medical cannabis portfolio while overlapping with Celadon in regulated medical cannabis API supply.

Regional players

  • Valeos Pharma A/S: Danish EU-GMP cultivator and Celadon's strategic collaboration partner since September 2024, enabling European supply from Danish facility. Comparable as an EU-based GMP cannabis cultivator and direct operational partner rather than a competitor.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Celadon Pharmaceuticals social profiles

Digital presence

Celadon Pharmaceuticals compliance and trust

Trust signal

Compliance6 records

Celadon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celadon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Celadon Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Celadon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celadon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celadon Pharmaceuticals

What does Celadon Pharmaceuticals do?

Celadon cultivates cannabis indoors and extracts and manufactures EU-GMP cannabinoid active pharmaceutical ingredients for pharmaceutical companies. Its commercial offer includes pharmaceutical-grade cannabis flower and oil APIs, high-THC API supplied through the UK Specials framework, cannabis genetics and intellectual-property licensing, and chronic-pain clinical services through LVL Health.

Is Celadon Pharmaceuticals a public or private company?

Celadon Pharmaceuticals is a public company. It is classified as public.

When was Celadon Pharmaceuticals founded?

Celadon Pharmaceuticals was founded in 2018. It employs 11 to 50 people.

Where is Celadon Pharmaceuticals based?

Celadon Pharmaceuticals is headquartered in London, United Kingdom, in the Europe region.

How does Celadon Pharmaceuticals make money?

Four revenue lines are on record. GMP Cannabis API Sales are the primary driver. The others are specials Framework Sales, IP Licensing Revenue and clinical Trial Data Services.

Who are Celadon Pharmaceuticals's main competitors?

Direct peers on record are GW Pharmaceuticals (Jazz Pharmaceuticals), Organigram Holdings, Khiron Life Sciences, MGC Pharmaceuticals and Oxford Cannabinoid Technologies. Broad incumbents are Tilray Brands, Canopy Growth, Aurora Cannabis and Cronos Group. Valeos Pharma A/S is listed as a regional player.

Does Celadon Pharmaceuticals have an API?

No public API is recorded for Celadon Pharmaceuticals.

What industry is Celadon Pharmaceuticals in?

Celadon Pharmaceuticals's product category is Cannabinoid Active Pharmaceutical Ingredients. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerCeladon raises GBP2 million, extends credit facilityCeladon Pharmaceuticals Plc has raised GBP2 million and extended its credit facility. The company is a UK-based pharmaceutical firm focused on the research, cultivation, and supply of cannabinoid-based medicines for chronic pain. This financing supports its operational activities and R&D efforts in the medical cannabis sector.MarketScreenerCeladon Pharma raises GBP2.0 million via placingCeladon Pharmaceuticals PLC raised GBP2.0 million through the placing of 1.7 million new shares at a 5.5% premium to its previous closing price. The company intends to use the proceeds for additional working capital to support deliveries under its first three supply contracts signed this year.Morningstar Financial ResearchTRADING UPDATES: Celadon Pharma raises GBP2.0 million via placingCeladon Pharmaceuticals PLC raised GBP2.0 million through the placing of 1.7 million new shares at a premium to its closing price, with proceeds designated for working capital. The company stated that this funding supports its current commitments following the signing of initial supply contracts and imminent deliveries to UK customers.LseTRADING UPDATES: Celadon Pharma raises GBP2.0 million via placingCeladon Pharmaceuticals PLC raised GBP2.0 million through the placing of 1.7 million new shares at a premium to its closing price, with proceeds designated for additional working capital. The company stated that the funding supports current commitments following the signing of three supply contracts and imminent deliveries to UK customers.CeladonpharmaRNS: Fundraise, Update on Future CLN Financing & TVRCeladon Pharmaceuticals Plc successfully raised £2.0 million in a recent fundraising effort, strengthening its financial position for at least the next 12 months. CEO James Short expressed gratitude towards shareholders for their support as the company focuses on improving patient lives with cannabis-based medicines.ProactiveinvestorsCannabis investment: budding revival as London's contenders adapt to changing marketLondon-listed cannabis companies including Celadon Pharmaceuticals, Chill Brands Group, and Oxford Cannabinoid Technologies are experiencing significant stock price increases as the sector adapts to evolving regulatory and market conditions. This revival is driven by tangible progress such as new manufacturing approvals, clinical trial advancements, and strategic pivots toward pharmaceutical or wellness models rather than speculative hype. The UK medical cannabis patient base is also expanding steadily, supported by growing domestic cultivation capabilities and increasing consumer demand for CBD products.Zapier£7 Million Committed Credit FacilityCeladon Pharmaceuticals Plc has secured a £7 million, two-year committed credit facility from a UK-based high net worth investor. The unsecured loan, carrying a 10% fixed interest rate, is intended to increase working capital headroom to support operations and fulfill recent product contract wins. This financing provides flexibility for the company to convert expressions of interest into formal sale contracts while it builds out necessary operational capabilities.dlvr.itCeladon receives good manufacturing practice approvalCeladon's UK midlands facility received MHRA GMP registration for its cannabis API, a prerequisite for commercializing its medicinal cannabis product. The approval follows four years of work and joins a select group of cannabis-focused pharmaceutical companies. The company expects its home office licence to be updated in due course.